Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Operating Margin (2020 - 2025)

Historic Operating Margin for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to 17.58%.

  • Cytek Biosciences' Operating Margin fell 93300.0% to 17.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.16%, marking a year-over-year decrease of 44100.0%. This contributed to the annual value of 10.24% for FY2024, which is 41900.0% up from last year.
  • According to the latest figures from Q3 2025, Cytek Biosciences' Operating Margin is 17.58%, which was down 93300.0% from 23.3% recorded in Q2 2025.
  • Over the past 5 years, Cytek Biosciences' Operating Margin peaked at 12.53% during Q2 2021, and registered a low of 36.12% during Q1 2025.
  • For the 5-year period, Cytek Biosciences' Operating Margin averaged around 8.6%, with its median value being 6.72% (2022).
  • Its Operating Margin has fluctuated over the past 5 years, first skyrocketed by 136700bps in 2021, then crashed by -260700bps in 2023.
  • Quarter analysis of 5 years shows Cytek Biosciences' Operating Margin stood at 3.39% in 2021, then tumbled by -95bps to 0.17% in 2022, then crashed by -235bps to 0.24% in 2023, then skyrocketed by 2308bps to 5.2% in 2024, then tumbled by -438bps to 17.58% in 2025.
  • Its Operating Margin was 17.58% in Q3 2025, compared to 23.3% in Q2 2025 and 36.12% in Q1 2025.